Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?
- 30 April 2006
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 130 (4) , 1357-1362
- https://doi.org/10.1053/j.gastro.2006.02.037
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Treating chronic hepatitis C with pegylated interferon alfa‐2a (40 KD) and ribavirin in clinical practiceAlimentary Pharmacology & Therapeutics, 2006
- Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis CGastroenterology, 2005
- Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3New England Journal of Medicine, 2005
- Treatment With Pegylated Interferon and Ribavarin in Hcv Infection With Genotype 2 Or 3 for 14 Weeks: A Pilot StudyHepatology, 2004
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis CHepatology, 2003
- Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis CGastroenterology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001